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ate (MTX) in Saudi patients.
Methods: Cross sectional study of adult patients on MTX, attending rheumatology drug mon-
itoring clinics in a university hospital, over a period of 24 weeks. Adverse drug reactions were
sought by patient interview, ﬁles review and laboratory abnormalities.
Results: Data collected included patients’ demographics, diagnoses, co-morbidities, MTX dose
and duration, other medications, laboratory abnormalities and adverse reactions, their severity,
preventability, and outcome. Out of a total of 593 patients screened, 186 (31.4%) using MTX were
interviewed. Most of the patients were female (88.5%). Adverse drug reactions (ADRs) were
detected in 61 patients (32.8%). Patients with ADRs took a mean dose of 12.9 mg (2.5–22.5 mg).
Ten ADRs (16.4% of total reactions) were preventable; they ranged between severe, moderate
and mild. The most common ADRs were gastrointestinal (GI) (52.5%), followed by anemia
(8.2%) and chest tightness (6.6%). The duration of the reaction ranged from few hours to 4 years.
Conclusion: In conclusion our patients with adverse reactions were younger, took less medica-
tions and had less co-morbidities. Our results were different from those published in the literature
relating MTX toxicity.
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lsevier1. Introduction
Methotrexate (MTX) usage extends over 50 years. It is widely
used as a disease modifying agent (DMARD) in rheumatoid
arthritis (RA) and psoriatic arthritis. Its use is still prevalent
even in the era of biological targeted therapy due to its thera-
peutically augmenting effects. It persisted because of its efﬁ-
cacy, acceptable toxicity proﬁle and low cost (Visser and Van
der Heijde, 2009). It is prescribed, alone or in combination with
other medications in RA and other connective tissue disorders
irrespective of the prognostic feature of the disease (Drugs for
Rheumatoid Arthritis, 2009; Saag et al., 2008). However, it is
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cells (Al-Niaimi and Cox, 2009). This toxicity ranges from mild
gastrointestinal side effects to more severe hematopoietic, he-
patic, pulmonary and renal effects (Al-Niaimi and Cox,
2009). In July 2004 the National Patient Safety Agency re-
corded 137 MTX related incidents in England in the previous
10 years including 25 deaths and 26 cases of serious harm
(Al-Niaimi and Cox, 2009; NHS National Patient Safety
Agency, 2006). Recent advances in genetic technology have
led to the investigation of the gene encoding enzyme in the
MTX metabolic pathways as possible determinants of MTX
efﬁcacy and toxicity and have suggested it to be race speciﬁc
(Ranganathan and McLeod, 2006). Studies in Caucasians
and African Americans found that genetic variation in MTX
intracellular transporter system may be an important determi-
nant in MTX related toxicity. It was suggested that the MTX
toxicity proﬁle may be distinct in different racial groups with
different genetic background (Ranganathan et al., 2008). This
prompted us to study adverse drug reactions in our population
which has not been studied before.
2. Methods
2.1. Subjects and methods
This is a cross sectional study conducted in a tertiary hospital
(King Khalid University Hospital, Riyadh). This hospital has
a very active rheumatology service with a busy practice cover-
ing hundreds of patients attending specialized clinics for mon-
itoring of anti-rheumatic drugs and their adverse drug
reactions. We included all adult patients (age more than
16 years) attending rheumatology drug monitoring clinics for
a period of 24 weeks. The study was approved by the Institu-
tional Review Board, at College of Medicine and King Khalid
University hospital, King Saud University, Riyadh and was
conducted in accordance with the Declaration of Helsinki.
We collected patients’ demographics, diagnoses, other co-mor-
bidities, especially those reported to inﬂuence the risk of
developing toxicities in previous studies namely; alcoholTable 1 Comparison between ADRs group and no
ADRs grou
Age (mean ± SD) 45.89 ± 11.
Number of medications (mean ± SD) 5.4 ± 1.7
Sex
Male 7 (11.5%)
Female 54 (88.5%)
Co morbidities 22 (41.5%)
Folic acid
Yes 47 (90.4%)
Diagnosis (n= 53)
Rheumatoid arthritis 38 (41.0%)
Systemic lupus erythematosus 3 (5.7%)
RA & SLE (overlap) 3 (5.7%)
Psoriatic arthritis 3 (5.7%)
Others 6 (11.3%)
* Signiﬁcant, RA = rheumatoid arthritis, SLE = systemintake, impaired renal function, hypo-albuminemia, human
immunodeﬁciency virus infections (HIV), hepatitis B infec-
tions, lung abnormality on chest X-ray, obesity and diabetes.
We also recorded MTX dose, duration, other medications
use, laboratory abnormalities. Adverse reactions were docu-
mented and their severity, preventability, duration and
outcome were noted. Both the World Health Organization
(WHO) and American Food and Drug Administration
(FDA) deﬁnitions were used to describe the adverse drug
reaction. WHO deﬁnes Adverse Drug Reaction (ADR) as ‘‘a
response to a drug which is noxious and unintended, and
which occurs in doses normally used in man for prophylaxis,
diagnosis or therapy of disease or for modiﬁcation of
physiological function’’ (International Drug Monitoring,
1969). FDA deﬁnes adverse event as any untoward medical
occurrence associated with the use of a drug in humans’’
(FDA, 2010). An adverse effect was deﬁned as ‘‘severe’’ when
the drug was permanently stopped, ‘‘moderate’’ when the drug
was temporarily stopped or the dose was adjusted and ‘‘mild’’
when no action was taken (Van Jaarsveld et al., 2000). The
ADRs were detected by patient interview, ﬁle review and
laboratory abnormalities. If an adverse drug reaction was
suspected, a form was ﬁlled which was designed by combining
the British National Formulary and Med Watch volunteer
reporting system (Appendix I) (British National Formulary,
2010; FDA, 2011). Since the reported events could be
related to the illness itself or to other drugs that most patients
used, a causal link was identiﬁed by using Narinjo scale (60
doubtful; 1–4 possible; 5–8 probable;P9 deﬁnite) for assessing
the probability of the reaction and McDonnell prevent-
ability questionnaire for the preventability of the reaction
(Appendices II and III) (Naranjo et al., 1981; McDonnell
and Jacobs, 2002).
2.2. Statistical analysis
All patients who entered the study were classiﬁed into two
groups, those with ADRs, and those with no ADRs. Data
were coded and entered into statistical package for socialADRs group.
p (n= 61) No ADRs (n= 125) P-value
7 51.51 ± 14.26 0.008*
5.89 ± 2.14 0.145
20 (16.0%) 0.411
105 (84.0%)
68.5%) 0.001*
119 (96.7%) 0.09
(n= 124)
97 (78.2%)
4 (3.2%) 0.572
2 (1.6%)
7 (5.6%)
14 (11.3%)
ic lupus erythematosus.
Table 2 Diagnoses compared between ADRs group and No
ADRs group.
ADRs group No ADRs
Male Female Male Female
RA 3 35 15 82
SLE 0 3 0 4
RA & SLE overlap 0 3 0 2
Psoriatic arthritis 2 1 3 4
Wegener’s granulomatosis 0 1
JCA 0 1 0 2
Ankylosing Spondylitis 0 2
Henoch Schonlein purpura 0 1
Scleroderma 0 1
Polymyositis 0 1
Adult-onset Still’s disease 1 0
Others 4 1 5
Total 5 48 20 104
RA= rheumatoid arthritis, SLE = systemic lupus erythematosus,
JCA= Juvenile chronic arthritis.
Table 3 Types of ADRs.
Type of ADR No %
GI 32 52.5
Anemia (Hb < 10 mg/dl) 5 8.2
Chest tightness 4 6.6
Fatigue 3 4.9
Alopecia 3 4.9
Urinary symptoms 2 3.3
Infection 2 3.3
Elevated liver enzymes (>2 times the normal) 1 1.6
Feels depressed 2 3.3
Increased stiﬀness 1 1.6
Photosensitivity 1 1.6
Pulmonary ﬁbrosis 1 1.6
Hyperglycemia 1 1.6
Oral ulcer 1 1.6
Dry mouth 1 1.6
Back pain 1 1.6
Total 61
GI = gastrointestinal.
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using student’s t test for continuous variables; chi square and
Fisher’s exact test for categorical variables. A p value of less
than 0.05 was considered signiﬁcant.3. Results
A total of 593 patients visited the outpatient rheumatology
drug monitoring clinic during the 24 week study period,186
patients (31.4% of total patients) were taking MTX. There
were 159 females (85.5%) and 27 males (14.5%) (Table 1).
The mean dose of MTX was 12.9 mg/week (2.5–22.5) mg of
methotrexate. The routes of administration were subcutane-
ous in one patient, intramuscular in two and the rest via oral
route with a mean therapeutic duration of 4.9 years. Out of
181 patients using MTX, 61 patients (32.8%) experienced at
least one adverse event 10 (16.4%) of ADRs could be
preventable according to McDonnell preventability question-
naire. Twelve (19.7%) of the events were severe and resulted
in drug discontinuation. Five (8.2%) were moderate. Out
of these moderate ADRs, one resulted in dose separation,
1 resulted in reducing the dose and 3 in more frequent
monitoring and follow up, the rest were classiﬁed as minor
and resulted in no alteration of therapy. The duration of
the reaction ranged from few hours after drug ingestion to
4 years.
One hundred and seven patients had other co-morbidities
(32 patients had hypertension, 32 diabetes mellitus, 55 other
bone and endocrine disorders). Patients with co-morbidities
in the ADR group were 22, and non ADR group were 85 with
a difference in favor of the non ADR group (p= 0.001). Most
of the patients in the ADR and non ADR group took folic acid
with no signiﬁcant difference between the two groups
(p= 0.09). The analysis of patient’s age between the two
groups showed that the patients with ADRs were younger than
those with no ADRs (p= 0.008). Patients with risk factors for
toxicity include 32 patients with diabetes mellitus (2 in the
ADR group and 30 in the non ADR group), 1 patient with
renal impairment in the non ADR group, one report of hepa-titis B infection in the non ADR group, two reports of positive
PPD (puriﬁed protein derivative) one in the ADR group and
the other in the non ADR. There was no difference between
male and female ratio in the two groups and in the number
of other medications usage. In most patients (41%) (Table 2)
MTX was being used to treat RA with no signiﬁcant difference
between the two groups (p= 0.734).
Causality assessment revealed that no reactions were
certain or deﬁnite, 9 were probable and 52 were possible
reactions. All included ADRs occurred after receiving metho-
trexate. Most common ADRs were gastrointestinal in nature
(52.5%) (Table 3) ranging from mild abdominal discomfort
to severe vomiting: vomiting in 1 (1.6%), diarrhea 1 (1.6%),
oral ulcer 1 (1.6%), nausea 6 (9.8%) and the rest were non-
speciﬁc abdominal discomfort (37.7%). Other common types
of ADRs included chest tightness (6.6%), anemia (8.2%),
fatigue (4.9%), and alopecia (4.9%).4. Discussion
Despite the introduction of new biological agents, MTX
monotherapy or in combination with other drugs is still con-
sidered an anchor treatment of many connective tissue disor-
ders (Katchamart et al., 2009). It is also considered to be the
most tolerable in long term therapy (Grove et al., 2001). Mon-
itoring is the key to minimize drug toxicity. This is the main
aim of the drug monitoring clinics in the study hospital. Risk
factors for MTX toxicity include alcohol intake, impaired re-
nal function, hypo-albuminemia, HIV infections, hepatitis B
infections, lung abnormality on chest X-ray, obesity and diabe-
tes (Visser et al., 2009). In our study these did not seem to lead
to increased incidence of ADRs. Our rate of non compliance as
a preventability factor (16.4%) was less than what was
reported in the literature (22.7%). In our study the number
of patients with other co-morbidities were greater in the
non-ADR group with signiﬁcant difference (p= 0.001).
Methotrexate dose was less than that reported in the literature
(17–20 mg/week) which may have contributed to reduction in
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Japanese (8 mg/week) (Visser and Van der Heijde, 2009; Kay
and Westhovens, 2009). Almost all patients (166 of 186;
89.2%) took folic acid therapy which is known to decrease
the toxicity of MTX especially GI side effects (Prey and Paul,
2009). Anemia encountered here was most likely not due to
MTX as it was not the type associated with MTX toxicity,
namely megaloblastic (Jones and Patel, 2000). Myalgia was
reported by one patient (1.6%) in our study. This complaint
has been reported in 20–30% of MTX treated patients (Jones
and Patel, 2000). People with ADRs were younger (p= 0.008)
which is different from what is published in the literature
(Al-Malaq et al., 2008). Withdrawal or spontaneous stopping
of the drug was mainly seen in patients who took combination
therapy. Most common adverse effects were gastrointestinal
(52.5%) in nature similar to other studies (53%), but higher
than in an Indian study (21%) (Van Jaarsveld et al., 2000;
Bahroo and Baba, 2006). These included nausea, vomiting,
diarrhea, oral ulcer and unspeciﬁc abdominal discomfort.
Toxicity leading to the discontinuation of the drug comprised
17% of ADRs which was higher than that reported in
literature (Van Jaarsveld et al., 2000). No adverse effects could
be named as being deﬁnitely associated with MTX according
to Narenjo scale (Naranjo et al., 1981). However no adverse
effects were irreversible or lethal.
No studies in Saudi or Arab patients have measured MTX
toxicity alone. Methotrexate was not mentioned in the few
studies done in Arab patients except one which mentioned that
side effects from analgesics and anti rheumatics were among
most common causes of ADRs, with a prevalence of 6.7%
of total reported ADRs and general preventability was 60%,
and patients were young, took more medications and were of-
ten females (Al-Malaq et al., 2008; Ahmed, 1997; Major et al.,
1998).
A main limitation of this study is that most ADRs are sub-
jective and almost all the patients took other medications, also
the study is open in nature and both the researcher and the pa-
tient know that the drug used is MTX which could lead to over
reporting of the side effects.
We recommend a patient safety booklet to document any
changes in MTX dose or in the side effects proﬁle as recom-
mended by previous studies (Al-Niaimi and Cox, 2009).
Application of diagnosis and monitoring data base (DIA-
MOND) program, in which data is entered by a specialized
rheumatology nurse to act as a communication tool between
medical and nursing staff. A telephone helping system could
also be used to keep patient compliant with all DMARDS
including MTX in the face of minor symptoms that might
otherwise result in unnecessary discontinuation (Grove
et al., 2001).
In conclusion 32.8% of Saudi patients using MTX experi-
enced at least one ADR. Most common ADRs reported were
GI. ADRs occurred in younger patients, in patients taking less
medications and in those who had less co-morbidities. Our re-
sults are different from those published in the literature regard-
ing MTX toxicity. A prospective study in our population may
help clarify these differences.Acknowledgments
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To assess the adverse reaction you should answer the following
questionnaire and give a score
Yes No Don’t
know
1 Are there previous conclusive reports of
this reaction?
+1 0 0
2 Did the adverse event appear after the
suspected drug was administered?
+2 1 0
3 Did the adverse reaction improved when
the suspected drug was discontinued or a
speciﬁc antagonist was administered?
+1 0 0
4 Did the adverse reaction reappear when
the drug was re-administered?
+2 1 0
5 Are there alternative causes that could on
their own cause the reaction?
1 +2 0
6 Did the reaction reappear when placebo
was given?
1 +1 0
7 Was the drug detected in the blood or
other body ﬂuids in concentrations
known to be toxic?
+1 0 0
8 Was the reaction more sever when the
dose was increased or less severe when the
dose was decreased?
+1 0 0
9 Did the patient have a similar reaction to
the same or similar drugs at any previous
exposure?
+1 0 0
10 Was the adverse event conﬁrmed by any
objective evidence?
+1 0 0
Total score
P9 Deﬁnite; 5–8 probable; 1–4 possible;
60 doubtfulNaranjo et al. (1981).A.III. Factors that determine the preventability of ADR
If the answer is yes to any of these questions the ADR is considered
preventable
Was the drug involved in the ADR not considered appropriate for
the patient’s clinical condition?
Were the dose, route, and frequency of administration not
appropriate for the patient’s weight and disease state?
Was required therapeutic drug monitoring or other necessary
laboratory test not performed?
Was there a history of allergy or previous reaction to the drug?
Was a drug interaction involved in the reaction?
Was a toxic serum drug concentration documented?
Was poor compliance involved in the reaction?References
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